The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
TTumour RResponse bby RECIST1 RECIST 1.0 0<br />
• CComplete l regression i (CR) (CR): 4 patients i (12 (12.0%) 0%)<br />
• Partial Regression (PR): 8 patients (23.5%)<br />
• Stable Disease (SD): 15 patients (44.0%)<br />
• Progressive Disease (PD): 7 patients (21.0%)<br />
• Tumour Response Rate: 11/34 (33.5%)<br />
• Disease Control Rate: 27/34 (79.5%) ( )<br />
– BCLC B 100%<br />
– BCLC C 68%<br />
• Mediantime-to-disease progression: 39 weeks(95% CI 27 – 73 wks)<br />
Response would be even higher with modified RECIST<br />
Pierce SGH Chow – Surgery FRCS,<br />
PhD<br />
12
Change language